Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Antwi K
Authors: Antwi K, Hepprich M, Reubi J, Christ E, Wild D,
Keywords: insulinoma, GLP-1R imaging,
Introduction: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Antwi A, Heye T, Fani M, Nicolas G, Merkle E,
Keywords: Insulinoma, neuroendocrine tumor, GLP-1R imaging,
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Raymond E
Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,
Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (p<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg tid after Wk 12. The extension phase (Wk 13 to Wk 48) is still ongoing
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Hörsch D
Authors: Hörsch D, Kulke M, Caplin M, Anthony L, Bergsland E,
Keywords: telotristat, carcinoid syndrome, tryptophan,
Introduction: EVE showed a significant improvement of 6.4 mo in median progression-free survival (PFS) vs PBO (HR 0.35, 95% CI 0.27-0.45; P<0.001) in patients (pts) with pNET in RADIANT-3.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Yao J, Pavel M, Lombard-Bohas C, Van Cutsem E, Lam D,
Keywords: everolimus, pNET, OS,